Abstract
Pharmacogenomics can be understood as the tailored treatment approach based on individual genomic structure. The treatment is where drug responses can vary with the genetic variant. Pharmacogenomics also determines genetic elements involved in a drug and its associated response. This concept of treatment has resulted in a new era of treatment, referred to as “personalized treatment.” Cancer is a disease where cancer cells abnormally multiply and progress fast, making treatment difficult. The different mutations or genetic signature and their developed resistance associated with the tumor make the treatment even grimmer. The treatment failure along with the need for safer therapies has led the development to shift to targeted therapies. These therapies in many cancers are more specific, safe, and effective when compared to cytotoxic which have a “one drug treat all” approach. Cancer biomarkers can be classified into two biomarkers, prognostic (related with disease outcome) and predictive (linked with response to drug treatment). Overall, pharmacogenomics data decreases the probability of adverse drug reactions and improves therapeutic value in cancer research.
This is a preview of subscription content, log in via an institution to check access.
References
Al-Mahayri ZN, Patrinos GP, Ali BR (2020) Toxicity and pharmacogenomic biomarkers in breast cancer chemotherapy. Front Pharmacol 11:445. https://doi.org/10.3389/fphar.2020.00445
Aneesh TP, Sonal Sekhar M, Jose A, Chandran L, Zachariah SM (2009) Pharmacogenomics: the right drug to the right person. J Clin Med Res 1(4):191–194. https://doi.org/10.4021/jocmr2009.08.1255
Ayoub N, Lucas C, Kaddoumi A (2011) Genomics and pharmacogenomics of breast cancer: current knowledge and trends. APJCP 12(5):1127–1140
Brandt B, Meyer-Staeckling S, Schmidt H, Agelopoulos K, Buerger H (2006) Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. Clin Cancer Res 12(24):7252–7260. https://doi.org/10.1158/1078-0432.CCR-06-0626
Calvo E, Walko C, Dees EC, Valenzuela B (2016) Pharmacogenomics, pharmacokinetics, and pharmacodynamics in the era of targeted therapies. Am Soc Clin Oncol Educ Book 35:e175–e184. https://doi.org/10.1200/EDBK_159061
Chan BA, Hughes BG (2015) Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 4(1):36–54. https://doi.org/10.3978/j.issn.2218-6751.2014.05.01
Chen JJ, Lu TP, Chen YC, Lin WJ (2015) Predictive biomarkers for treatment selection: statistical considerations. Biomark Med 9(11):1121–1135. https://doi.org/10.2217/bmm.15.84
Crisafulli C, Romeo PD, Calabrò M, Epasto LM, Alberti S (2019) Pharmacogenetic and pharmacogenomic discovery strategies. Cancer Drug Resist 2:225–241. https://doi.org/10.20517/cdr.2018.008
Funston G, Hamilton W, Abel G, Crosbie EJ, Rous B, Walter FM (2020) The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: a population-based cohort study. PLoSMed 17(10):e1003295. https://doi.org/10.1371/journal.pmed.1003295
Gagno S, Bartoletti M, Romualdi C, Poletto E, Scalone S, Sorio R, Zanchetta M, Mattia ED, Roncato R, Cecchin E, Giorda G, Toffoli G (2020) Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer. Pharmacogenomics 21(14):995–1010. https://doi.org/10.2217/pgs-2020-0049
Hattinger CM, Patrizio MP, Luppi S, Serra M (2020) Pharmacogenomics and pharmacogenetics in osteosarcoma: translational studies and clinical impact. Int J Mol Sci 21(13):4659. https://doi.org/10.3390/ijms21134659
Hess G, Fonseca E, Scott R, Fagerness J (2015) Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. Genet Res 97:E13. https://doi.org/10.1017/S0016672315000099
Kitzmiller JP, Groen DK, Phelps MA, Sadee W (2011) (2011). Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med 78(4):243–257. https://doi.org/10.3949/ccjm.78a.10145
Lauschke VM, Milani L, Ingelman-Sundberg M (2018) Pharmacogenomic biomarkers for improved drug therapy – recent progress and future developments. AAPS J 20:4. https://doi.org/10.1208/s12248-017-0161-x
Lu DY, Lu TR, Xu B, Ding J (2015) Pharmacogenetics of cancer therapy: breakthroughs from beyond? Future Sci OA 1(4):FSO80. https://doi.org/10.4155/fso.15.80
Müller DJ, Rizhanovsky Z (2020) From the origins of pharmacogenetics to first applications in psychiatry. Pharmacopsychiatry 53(4):155–161. https://doi.org/10.1055/a-0979-2322. Epub 2019 Sep 23
Nalejska E, Mączyńska E, Lewandowska MA (2014) Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther 18(3):273–284. https://doi.org/10.1007/s40291-013-0077-9
Papachristos A, Sivolapenko GB (2020) Pharmacogenomics, pharmacokinetics and circulating proteins as biomarkers for bevacizumab treatment optimization in patients with cancer: a review. J Pers Med 10(3):79. https://doi.org/10.3390/jpm10030079
Primorac D, Bach-Rojecky L, Vađunec D, Juginović A, Žunić K, Matišić V, Skelin A, Arsov B, Boban L, Erceg D, Ivkošić IE, Molnar V, Ćatić J, Mikula I, Boban L, Primorac L, Esquivel B, Donaldson M (2020) Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data. Pharmacogenomics 21(2):141–156. https://doi.org/10.2217/pgs-2019-0134
Rodríguez-Antona C, Taron M (2015) Pharmacogenomic biomarkers for personalized cancer treatment. J Intern Med 277(2):201–217. https://doi.org/10.1111/joim.12321
Rodríguez-Vicente A, Lumbreras E, Hernández J, Martín M, Calles A, Otín C, Algarra S, Páez D, Taron M (2016) Pharmacogenetics and pharmacogenomics as tools in cancer therapy. Drug Metab Pers Ther 31(1):25–34. https://doi.org/10.1515/dmpt-2015-0042
Sanchez-Spitman AB, Swen JJ, Dezentje VO, Moes D, Gelderblom H, Guchelaar HJ (2019) Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. Expert Rev Clin Pharmacol 12(6):523–536. https://doi.org/10.1080/17512433.2019.1610390
Sargent DJ, Marsoni S, Thibodeau SN, Labianca R, Hamilton SR, Torri V, Monges G, Ribic C, Grothey A, Gallinger S (2008) Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol 26(15_Suppl):4008. https://doi.org/10.1200/jco.2008.26.15_suppl.4008
Singh DB (2020) The impact of pharmacogenomics in personalized medicine. Adv Biochem Eng Biotechnol 171:369–394. https://doi.org/10.1007/10_2019_110
Strimpakos A, Syrigos K, Saif M (2009) Pharmacogenetics and biomarkers in colorectal cancer. Pharmacogenomics J9:147–160. https://doi.org/10.1038/tpj.2009.8
Thorsten Z, Barbara E, Raymonde B, Tina D, Sonja H, Dirk W, Andreas B, Jennifer E, Manuela B, Georg H, Manfred H, Michael H, Hartmut D, Stephan S (2010) TP53 Mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28(29):4473–4478. https://doi.org/10.1200/JCO.2009.27.8762
Tonry C, Finn S, Armstrong J, Pennington SR (2020) Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management. Clin Proteomics 17:41. https://doi.org/10.1186/s12014-020-09305-7
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 6:201. https://doi.org/10.1038/s41392-021-00572-w
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2024 Springer Nature Singapore Pte Ltd.
About this entry
Cite this entry
Sudha, Yadav, M., Kumar, A., Tushir, S., Rawat, R. (2024). Role of Pharmacogenomics in Tumor and Therapeutic Outcomes. In: Sobti, R.C., Ganguly, N.K., Kumar, R. (eds) Handbook of Oncobiology: From Basic to Clinical Sciences. Springer, Singapore. https://doi.org/10.1007/978-981-99-6263-1_58
Download citation
DOI: https://doi.org/10.1007/978-981-99-6263-1_58
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-6262-4
Online ISBN: 978-981-99-6263-1
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences